A new review highlights the need to simultaneously control CKD-MBD and MICS in patients receiving hemodialysis.
Promising therapies still need to be further evaluated in clinical trials.
Secondary hyperparathyroidism remains uncontrolled in many patients with chronic kidney disease.
Recent studies have shown the importance of starting treatment at lower phosphorus and PTH levels on long-term outcomes of SHPT.
Despite the increasing availability of calcimimetics, parathyroidectomy rates in the US have gradually increased.
Patients at risk for postoperative hypocalcemia need more vigilant postoperative monitoring.
Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation.
Hypercalcemia was common among kidney transplant recipients at 3 months, investigators reported.
Use of home dialysis and modalities other than conventional in-center hemodialysis is expected to grow.
Switching from oral to intravenous calcimimetic may lower PTH levels in patients on hemodialysis with poor tolerance.